Clinical Trial Detail

NCT ID NCT02187744
Title A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Recruitment Completed
Gender
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications

Her2-receptor positive breast cancer

Therapies

Carboplatin + Docetaxel + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST